Ad hoc: GPC Biotech AG: GPC Biotech Appoints Torsten Hombeck as Chief Financial Officer

12/4/2007, 2:44 PM (Source: GlobeNewswire)

Martinsried/Munich (Germany) and Princeton, N.J., December 4, 2007 -
GPC Biotech AG (Frankfurt Stock Exchange: GPC; TecDAX index; NASDAQ:
GPCB) today announced the appointment of Torsten Hombeck, Ph.D., to
Chief Financial Officer. Dr. Hombeck will assume his duties on
January 1, 2008. Dr. Hombeck will replace Mirko Scherer, Ph.D., who
is resigning from the Company, effective immediately, to pursue other
interests. Dr. Scherer will remain a consultant to GPC Biotech.

Torsten Hombeck, Ph.D., joined GPC Biotech in 1999. Dr. Hombeck has
worked out of the Company's U.S. offices as Vice President, Finance
since 2002, and he will continue to be based in Princeton, New
Jersey. Dr. Hombeck has played an integral role in GPC Biotech's
financings, including IPOs on both the Frankfurt Stock Exchange and
on NASDAQ. He was also intimately involved in the Company's two
previous M&A transactions with Mitotix, Inc. in the U.S. and with
Axxima Pharmaceuticals in Germany. In addition, he has been
instrumental in building the Finance department at GPC Biotech and
ensuring that the many reporting obligations of a dual-listed
corporation are met. Prior to joining GPC Biotech, he held positions
in corporate finance and controlling, including financial oversight
responsibility for South America, at Beiersdorf AG, an international
branded consumer products company. Dr. Hombeck holds a Masters
degree in business administration as well as a Ph.D. in Finance from
the European Business School, Oestrich-Winkel, Germany.


This ad hoc announcement contains forward-looking statements, which
express the current beliefs and expectations of the management of GPC
Biotech, including financial projections and forecasts relating to
our operations and financial situation. Such statements are based on
current expectations and are subject to risks and uncertainties, many
of which are beyond our control, that could cause future results,
performance or achievements to differ significantly from the results,
performance or achievements expressed or implied by such
forward-looking statements. Actual results could differ materially
depending on a number of factors, and we caution investors not to
place undue reliance on the forward-looking statements contained in
this ad hoc announcement. We direct you to GPC Biotech's Annual
Report on Form 20-F for the fiscal year ended December 31, 2006 and
other reports filed with the U.S. Securities and Exchange Commission
for additional details on the important factors that may affect the
future results, performance and achievements of GPC Biotech.
Forward-looking statements speak only as of the date on which they
are made and GPC Biotech undertakes no obligation to update these
forward-looking statements, even if new information becomes available
in the future.

For further information, please contact:

GPC Biotech AG
Martin Braendle
Director, Investor Relations & Corporate Communications
Phone: +49 (0)89 8565-2693

In the U.S.: Laurie Doyle
Director, Investor Relations & Corporate Communications
Phone: +1 609 524 5884

--- End of Message ---

GPC Biotech AG
Fraunhoferstr. 20 Martinsried

WKN: 585150; ISIN:
DE0005851505; Index: CDAX, MIDCAP, Prime All Share, TecDAX, HDAX,
TECH All Share;
Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in
Börse Berlin,
Freiverkehr in Bayerische Börse München, Freiverkehr in Börse
Freiverkehr in Börse Stuttgart, Freiverkehr in Hanseatische
Wertpapierbörse zu Hamburg,
Geregelter Markt in Frankfurter Wertpapierbörse;
Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.